Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Gerresheimer    GXI   DE000A0LD6E6

GERRESHEIMER (GXI)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Gerresheimer : wows at CPhI China with innovative packaging solutions

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/19/2018 | 08:58am CEST

Düsseldorf/Shanghai, June 19, 2018 - Gerresheimer is presenting new products such as the Gx InnoSafe, the metal-free RTF syringe, and RTF vials at the CPhI China trade fair in Shanghai from June 20 to 22, 2018 (SNIEC, booth N5P21). Inhalers and injection pens will also be on show, along with glass vials, ampoules, and cartridges as well as plastic medicine containers. Many of these products are manufactured at Gerresheimer's own plants in China and India.

'To make sure our customers at CPhI China have all the information they need, we are showcasing our highlights from CPhI Worldwide and Pharmapack Europe,' says David Tsoe, Sales Director Primary Packaging Glass by Gerresheimer Shuangfeng.

An Asian debut at CPhI China for the Gx InnoSafe

With the Gx InnoSafe, Gerresheimer offers a syringe with an integrated passive safety system that avoids inadvertent needlestick injuries and prevents the syringe from being reused. It is designed with pharmaceutical companies' production processes in mind as well as being optimized for simple and intuitive use by medical professionals.

Metal-free 1 ml long Luerlock Gx RTF syringe

By developing an innovative, patent-pending manufacturing technology, Gerresheimer has succeeded in readying its metal-free 1 ml long Luerlock Gx RTF syringe for series production. Traces of tungsten or other metals occasionally remain in the drilled hole when the cone of a syringe is moulded, which can cause problems when the syringes are used. There is therefore a need for pre-fillable syringe systems that ideally eliminate the risk of metal contaminants, particularly for drugs based on bioengineered active substances.

Disclaimer

Gerresheimer AG published this content on 19 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 19 June 2018 06:57:07 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GERRESHEIMER
07/12GERRESHEIMER : Slide show results
CO
07/11GERRESHEIMER : extends business model and increases growth forecast
PU
07/11GERRESHEIMER : acquires Sensile Medical / irrespective of that, increased growth..
EQ
07/11GERRESHEIMER : Acquisition
CO
07/09GERRESHEIMER AG : half-yearly earnings release
06/30GERRESHEIMER : Half-year report
CO
06/28GERRESHEIMER AG : Preliminary announcement of the publication of financial repor..
EQ
06/25GERRESHEIMER : an Innovative Learning Location
PU
06/19GERRESHEIMER : wows at CPhI China with innovative packaging solutions
PU
06/14GERRESHEIMER AT MAKEUP IN PARIS : Glass for unmistakable cosmetic products
PU
More news
News from SeekingAlpha
04/13Gerresheimer AG ADR 2018 Q1 - Results - Earnings Call Slides 
02/23Gerresheimer AG ADR 2017 Q4 - Results - Earnings Call Slides 
2017Gerresheimer AG ADR 2017 Q3 - Results - Earnings Call Slides 
2015Corning buying German pharma glass tubing business for $219m 
Financials (€)
Sales 2018 1 360 M
EBIT 2018 181 M
Net income 2018 125 M
Debt 2018 728 M
Yield 2018 1,58%
P/E ratio 2018 18,63
P/E ratio 2019 20,97
EV / Sales 2018 2,27x
EV / Sales 2019 2,14x
Capitalization 2 361 M
Chart GERRESHEIMER
Duration : Period :
Gerresheimer Technical Analysis Chart | GXI | DE000A0LD6E6 | 4-Traders
Technical analysis trends GERRESHEIMER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 72,6 €
Spread / Average Target -3,5%
EPS Revisions
Managers
NameTitle
Axel Herberg Chairman-Supervisory Board
Rainer Beaujean Chief Financial Officer
Theodor Stuth Independent Member-Supervisory Board
Udo J. Vetter Independent Member-Supervisory Board
Francesco Grioli Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
GERRESHEIMER8.80%2 759
MEDTRONIC PLC9.42%119 437
BAXTER INTERNATIONAL15.69%40 217
ALIGN TECHNOLOGY63.58%29 130
ZIMMER BIOMET HOLDINGS-4.79%23 354
HOYA CORPORATION10.59%21 544